The funding will support further development of an existing serum-based assay and expansion of the test to use saliva samples.
Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer.
Funds will support projects aimed at earlier identification of patients who can benefit from treatment.
The firm is developing a wirelessly enabled biosensor patch that would continuously monitor several blood-glucose biomarkers for diabetes patients.
Under a new deal, EKF's BHB assay is now available for use on Ortho's Vitros 4600 chemistry system and the Vitros 5600 integrated system.
In a study of genetic variants associated with glycated hemoglobin in a meta-analysis, researchers found a G6PD variant leading to deceptively low blood sugar levels.
Roche's HbA1c test, along with an immunoassay system from Shenzhen New Industries Biomedical, and a celiac test from Immco also received 510(k) clearance last month.
On a conference call, the firm's CEO said that it and other industry players are pushing to postpone implementation of PAMA to no earlier than July 1, 2018.
Axon will distribute Biosurfit's POC instrument as part of the deal, which follows earlier agreements between the two firms covering Austria, Croatia, Slovakia, the Czech Republic, and Slovenia.
The assay can also be used to assess a broad range of metabolic conditions, including pancreatic tumors, liver disease, acromegaly, and others.